Novo Nordisk said on Thursday it filed a marketing application to the U.S. Food and Drug Administration for CagriSema, its once-weekly next-generation weight-loss drug.

Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

ZURICH, Dec 18 () - Swiss pharma giants Novartis and Roche on Thursday backed U. efforts to lower the ​cost of drugs and are ...

Eli Lilly's oral pill helped maintain weight loss in patients switching from injectable versions of GLP-1 drugs, the company ...

WASHINGTON, Dec 18 (Reuters) - Americans enrolled in Medicare will pay about 50% less out of pocket in 2026 for some drugs including ​Pfizer and Bristol Myers Squibb's blood thinner Eliquis and Merck ...

Dec 18 (Reuters) - European shares were ‌muted ​on Thursday as investors ‌adopted a largely cautious stance ahead of ​a ...

European shares rose on Thursday as lower-than-expected U.S. inflation strengthened hopes for Federal Reserve interest rate ...

European shares were largely muted on Thursday as declines in heavyweight healthcare and financials limited broader gains and ...

Indian stocks traded higher on Thursday, with the Sensex and Nifty making a sharp U-turn. Uncertainty over a potential ...

Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...